

- The efficacy and safety profile of fingolimod, an orally active sphingosine 1-phosphate receptor modulator, has been well characterized in a large clinical development program.
- The study evaluated safety and tolerability of fingolimod in relapsing-remitting multiple sclerosis (RRMS) patients from Latin America.
- This was a 16-week, single treatment arm, open-label, multi-center study aimed to evaluate safety and tolerability of fingolimod in RRMS patients predominantly from Latin American countries.
- The first dose of fingolimod 0.5 mg was well tolerated in RRMS patients from Latin America.
- The overall safety profile was clinically manageable and consistent with previous fingolimod studies.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Novartis. Medical writing assistance for this study was provided by Rahul Birari of Novartis Healthcare Pvt. Ltd and funded by Novartis. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).